{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:42Z","timestamp":1786119282115,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1097\/cad.0b013e32811d69cb","type":"journal-article","created":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T18:16:40Z","timestamp":1612808200000},"page":"977-980","source":"Crossref","is-referenced-by-count":20,"title":["Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered"],"prefix":"10.1097","volume":"18","author":[{"given":"Laurence","family":"V\u00e9nat-Bouvet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Saint-Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lebrun-Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Tubiana-Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210203","first-page":"2747","article-title":"Irinotecan metabolism and disposition in cancer patients","volume":"4","author":"Sparreboom","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R2-16-20210203","first-page":"423","article-title":"Pharmacokinetics, metabolism, and excretion of irinotecan (CP-T11) following IV infusion of [14C]CPT-11 in cancer patients","volume":"28","author":"Slatter","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R3-16-20210203","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-2952(96)00457-1","article-title":"Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamtothecin (SN-38), by human liver carboxylesterase","volume":"52","author":"Rivory","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"R4-16-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/oxfordjournals.annonc.a059109","article-title":"Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials","volume":"6","author":"Chabot","year":"1995","journal-title":"Ann Oncol"},{"key":"R5-16-20210203","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00003088-199733040-00001","article-title":"Clinical pharmacokinetics of irinotecan","volume":"33","author":"Chabot","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R6-16-20210203","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00685737","article-title":"Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine","volume":"36","author":"Lokiec","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"R7-16-20210203","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0378-4347(99)00452-1","article-title":"Sensitive determination of irinotecan and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry","volume":"736","author":"Ragot","year":"1999","journal-title":"J Chromatogr B"},{"key":"R8-16-20210203","article-title":"GPR Anticancer drugs. Guide to prescription drugs in patient with chronic renal failure. 2nd ed","author":"Launay-Vacher","year":"2003"},{"key":"R9-16-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0305-7372(90)90060-S","article-title":"Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo","volume":"17","author":"Sauer","year":"1990","journal-title":"Cancer Treat Rev"},{"key":"R10-16-20210203","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/annonc\/mdg493","article-title":"A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863","volume":"14","author":"Venook","year":"2003","journal-title":"Ann Oncol"},{"key":"R11-16-20210203","first-page":"60","article-title":"Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure","volume":"2005","author":"Stemmler","year":"2002","journal-title":"Onkologie"},{"key":"R12-16-20210203","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1179\/joc.2005.17.4.452","article-title":"Good tolerance of weekly irinotecan in patients with metastatic colorectal cancer on chronic hemodialysis","volume":"17","author":"Budakoglu","year":"2005","journal-title":"J Chemother"},{"key":"R13-16-20210203","first-page":"397","article-title":"Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer","volume":"32","author":"Shinozaki","year":"2005","journal-title":"Gan To Kagaku Ryoho"},{"key":"R14-16-20210203","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R15-16-20210203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.canlet.2005.04.040","article-title":"Role of pharmacogenetics in irinotecan therapy","volume":"234","author":"De Jong","year":"2006","journal-title":"Cancer Lett"},{"key":"R16-16-20210203","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00280-005-0166-5","article-title":"Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma, and saliva data in patients with metastatic digestive cancer receiving FOLFIRI regimen","volume":"58","author":"Poujol","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-16-20210203","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov Today"},{"key":"R18-16-20210203","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2003.10.003","article-title":"Pharmacodynamic properties of EGFR inhibitors under clinical investigation [review]","volume":"30","author":"Thomas","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"R19-16-20210203","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2005.04.029","article-title":"Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma","volume":"41","author":"Delbaldo","year":"2005","journal-title":"Eur J Cancer"},{"key":"R20-16-20210203","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","article-title":"Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study","volume":"21","author":"Takimoto","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Suppl 15","key":"R21-16-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0093-7754(03)00401-9","article-title":"Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group Study","volume":"30","author":"Takimoto","year":"2003","journal-title":"Semin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001813-200709000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:58:05Z","timestamp":1786039085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200709000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e32811d69cb","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}